by Vandana Singh | Jun 30, 2026 | General
The U.S. Food and Drug Administration (FDA) accepted on Tuesday Sarepta Therapeutics Inc.’s (NASDAQ:SRPT) supplemental New Drug Applications seeking to convert the accelerated approvals of AMONDYS 45 (casimersen) and VYONDYS 53 (golodirsen) into traditional approvals...
by Vandana Singh | Jun 30, 2026 | General
Genmab A/S – ADR (NASDAQ:GMAB) on Monday shared topline results from the Phase 3 EPCORE DLBCL-4 trial. The trial evaluated the combination of fixed-duration epcoritamab and lenalidomide, compared to standard-of-care, rituximab plus gemcitabine plus oxaliplatin...
by Vandana Singh | Jun 30, 2026 | General
Genmab A/S – ADR (NASDAQ:GMAB) on Monday shared topline results from the Phase 3 EPCORE DLBCL-4 trial. The trial evaluated the combination of fixed-duration epcoritamab and lenalidomide, compared to standard-of-care, rituximab plus gemcitabine plus oxaliplatin...
by Benzinga Insights | Jun 30, 2026 | General
Caterpillar (NYSE:CAT) has outperformed the market over the past 15 years by 4.21% on an annualized basis producing an average annual return of 16.34%. Currently, Caterpillar has a market capitalization of $501.10 billion. Buying $1000 In CAT: If an investor had...
by Benzinga Insights | Jun 30, 2026 | General
Caterpillar (NYSE:CAT) has outperformed the market over the past 15 years by 4.21% on an annualized basis producing an average annual return of 16.34%. Currently, Caterpillar has a market capitalization of $501.10 billion. Buying $1000 In CAT: If an investor had...
Recent Comments